imipramine has been researched along with caffeine in 112 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 38 (33.93) | 18.7374 |
| 1990's | 6 (5.36) | 18.2507 |
| 2000's | 24 (21.43) | 29.6817 |
| 2010's | 44 (39.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Browne, RG; Howard, HR; Koe, BK; Lebel, LA; Sarges, R; Seymour, PA | 1 |
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L | 1 |
| Butler, DE; Marriott, JG; Poschel, BP | 1 |
| Blake, JF; Curatolo, WJ; Lombardo, F | 1 |
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Duffy, EM; Jorgensen, WL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Faassen, F; Spanings, H; Vogel, G; Vromans, H | 1 |
| Carrupt, PA; Martel, S; Ottaviani, G | 1 |
| Akamatsu, M; Fujikawa, M; Nakao, K; Shimizu, R | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Alimuddin, M; Bulloch, D; Dahl, R; Grant, D; Lee, N; Peacock, M | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Andrisano, V; Barril, X; Bartolini, M; Carreiras, Mdo C; de los Ríos, C; García, AG; Huertas, O; León, R; López, B; López, MG; Luque, FJ; Marco-Contelles, J; Rodríguez-Franco, MI; Samadi, A; Villarroya, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Andrisano, V; Arce, MP; Badia, A; Bartolini, M; Camps, P; Clos, MV; Dafni, T; Formosa, X; Galdeano, C; Gómez, E; Huertas, O; Isambert, N; Lavilla, R; Luque, FJ; Mancini, F; Muñoz-Torrero, D; Ramírez, L; Rodríguez-Franco, MI | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Arce, MP; Conde, S; García, AG; González-Muñoz, GC; López, B; López, MG; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Akamatsu, M | 1 |
| Sen, S; Sinha, N | 1 |
| Arce, MP; Conde, S; del Barrio, L; Egea, J; García, AG; González-Muñoz, GC; León, R; López, B; López, MG; Martín-de-Saavedra, MD; Pérez, C; Rodríguez-Franco, MI; Romero, A; Villarroya, M | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Chen, ZF; Huang, SL; Huang, ZS; Liang, H; Qin, JK; Tang, H; Zhao, HT; Zhao, LZ; Zhong, SM | 1 |
| Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
| Barber, S; Dew, TP; Farrell, TL; Poquet, L; Williamson, G | 1 |
| Chen, ZF; Liang, H; Tang, H; Wang, ZY; Zhao, HT; Zhong, SM | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G | 1 |
| Chen, W; Huangli, Y; Qin, J; Shen, Y; Tang, H; Wang, L; Wei, S | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Yang, X; Zheng, Y | 1 |
| Ai, J; Deng, Y; Li, Y; Liu, Q; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xu, R; Yang, X; Zheng, Y | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, X | 1 |
| Arce, MP; Conde, S; Egea, J; Gil, C; León, R; López, MG; Monjas, L; Pérez, C; Rodríguez-Franco, MI; Villarroya, M | 1 |
| Bai, P; Leng, C; Li, X; Liu, W; Ma, Q; Pan, W; Sang, Z; Tan, Z; Wang, K; Xu, Q; Yang, Y; Yu, L | 1 |
| Liu, W; Ma, Q; Pan, W; Sang, Z; Wang, K; Yu, L | 1 |
| Han, X; Liu, W; Ma, Q; Sang, Z; Wang, H; Wang, K; Ye, M; Yu, L | 2 |
| Huang, Q; Jiang, N; Li, Q; Liang, N; Liu, J; Xie, SS | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Xu, R; Yang, J; Zhang, X | 1 |
| Handzlik, J; Jastrzębska-Więsek, M; Kieć-Kononowicz, K; Kucwaj-Brysz, K; Latacz, G; Lubelska, A; Partyka, A; Wesołowska, A | 1 |
| Deng, Y; Li, Y; Liu, H; Song, Q; Tan, Z; Xiao, G; Xu, R; Yang, Z; Zhang, X; Zheng, Y | 1 |
| An, Q; Deng, Y; Liu, P; Luo, Y; Sang, Z; Tang, Y; Wang, T; Yang, T; Yang, Y; Zhang, T | 1 |
| Alcaro, S; Bagetta, D; Borges, F; Cagide, F; Oliveira, PJ; Ortuso, F; Pérez, C; Reis, J; Rodríguez-Franco, MI; Teixeira, J; Uriarte, E; Valencia, ME | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Deng, Y; He, Y; Li, W; Liu, H; Qiang, X; Song, Q; Tan, Z; Ye, C | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Fan, X; Liu, W; Sang, Z; Shi, J; Wang, K; Yang, D; Zhang, P; Zhang, Z; Zhu, G | 1 |
| Bai, P; Cheng, X; Cheng, Y; Lu, X; Sang, Z; Shi, J; Wang, K; Yang, J; Zhang, P; Zhang, Q; Zheng, C | 1 |
| Illnerová, H; Vanĕcek, J | 1 |
| Daleva, L; Stefanova, D | 1 |
| Gross, MD | 1 |
| Good, MI | 1 |
| Auclair, MC; Lechat, P; Vernimmen, C | 1 |
| Baudry, M; Jones, RS; Olpe, HR | 1 |
| Holloway, FA; Shull, RN | 1 |
| Färber, G; Fraling, F; Herz, A; Niedner, I | 1 |
| Greengard, P; Quinn, GP; Reid, MB | 1 |
| Haslam, RJ; Rosson, GM | 1 |
| Forte, JG; Ray, TK | 1 |
| Mlejnkova, M; Rysánek, K; Spánkova, H; Synek, P | 1 |
| Mennear, JH; Rudzik, AD | 1 |
| Boissier, JR; Larousse, C; Simon, P; Villeneuve, A | 1 |
| Busca, GP | 1 |
| Oliverio, A | 1 |
| Bouttier, D; Julou, L; Sigwald, J; Thomas, J | 1 |
| Hata, T; Kita, T; Murakami, T | 1 |
| Oldendorf, WH | 1 |
| Allen, LE; Ferguson, HC; McKinney, GR | 1 |
| Andersson, KE | 1 |
| Gordon, JL | 1 |
| Baden, MM; Valanju, NN; Valanju, SN; Verma, SK | 1 |
| Greenwood, DT; Sommerville, AR | 1 |
| Nieschulz, O | 1 |
| Senault, B | 1 |
| Laplace, JP; Ruckebusch, Y | 1 |
| Hakano, N | 1 |
| Irikura, T; Ishiko, J; Iwaki, R; Kudo, Y | 1 |
| Bättig, K; Wanner, HU | 1 |
| Collins, RJ; Simonton, VR | 1 |
| Cassone, MC; Fundarò, A; Molinengo, L | 1 |
| Fundarò, A; Molinengo, L; Ricci Gamalero, S | 1 |
| Greenberg, SH; Levin, RM; Shofer, J | 1 |
| Kuribara, H | 1 |
| de Meis, L; Wolosker, H | 1 |
| Badar, SK; Kline, JA; Marcengill, MB; Watts, JA; Yates, KM | 1 |
| RUDOLPH, AS; SEWELL, HH; WHITE, RP | 1 |
| METYS, J; METYSOVA, J | 1 |
| Carvalho-Netto, EF; Nunes-de-Souza, RL | 1 |
| Amaral, VC; Campos, KF; Miguel, TT; Nunes-de-Souza, RL; Rico, JL | 1 |
| Bohner, LO; Costa, AP; De Lima, TC; Lino-de-Oliveira, C; Santos, EC; Silva, CF; Vieira, C | 1 |
1 review(s) available for imipramine and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for imipramine and caffeine
| Article | Year |
|---|---|
Caffeine in the treatment of children with minimal brain dysfunction or hyperkinetic syndrome.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Caffeine; Child; Child, Preschool; Clinical Trials as Topic; Dextroamphetamine; Humans; Hyperkinesis; Imipramine; Methylphenidate | 1975 |
110 other study(ies) available for imipramine and caffeine
| Article | Year |
|---|---|
4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Cats; Cell Membrane; Cerebral Cortex; Chemical Phenomena; Chemistry; Corpus Striatum; Male; Molecular Structure; Motor Activity; Purinergic Antagonists; Quinoxalines; Rats; Receptors, Purinergic; Sleep; Structure-Activity Relationship; Triazoles | 1990 |
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Topics: Amnesia; Animals; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Electroshock; Humans; Male; Mice; Mice, Inbred Strains; Pyrrolidines; Structure-Activity Relationship | 1984 |
Cognition-activating properties of 3-(Aryloxy)pyridines.
Topics: Animals; Cognition; Dose-Response Relationship, Drug; Male; Mice; Psychotropic Drugs; Pyridines; Structure-Activity Relationship | 1981 |
Computation of brain-blood partitioning of organic solutes via free energy calculations.
Topics: Animals; Blood-Brain Barrier; Brain; Cattle; Cells, Cultured; Endothelium, Vascular; Membrane Lipids; Microcirculation; Molecular Conformation; Molecular Structure; Monte Carlo Method; Permeability; Pharmaceutical Preparations; Software; Solubility; Thermodynamics | 1996 |
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of drug solubility from Monte Carlo simulations.
Topics: Monte Carlo Method; Pharmaceutical Preparations; Solubility | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Caco-2 Cells; Cell Membrane Permeability; Heterocyclic Compounds; Humans; Protein Transport | 2003 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
Topics: Humans; Membranes, Artificial; Models, Biological; Models, Molecular; Octanols; Permeability; Pharmaceutical Preparations; Skin Absorption; Water | 2007 |
QSAR study on permeability of hydrophobic compounds with artificial membranes.
Topics: Biological Transport; Caco-2 Cells; Drug Evaluation, Preclinical; Humans; Hydrophobic and Hydrophilic Interactions; Membranes, Artificial; Permeability; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Determination of log D via automated microfluidic liquid-liquid extraction.
Topics: Automation; Biopharmaceutics; Microfluidic Analytical Techniques; Pharmacokinetics | 2008 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Blood-Brain Barrier; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catalytic Domain; Cell Death; Cell Line, Tumor; Cholinesterase Inhibitors; Cytosol; Dihydropyridines; Humans; Hydrogen Peroxide; Kinetics; Ligands; Models, Molecular; Peptide Fragments; Permeability; Tacrine | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Pyrano[3,2-c]quinoline-6-chlorotacrine hybrids as a novel family of acetylcholinesterase- and beta-amyloid-directed anti-Alzheimer compounds.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Drug Design; Humans; Isomerism; Membranes, Artificial; Mice; Models, Molecular; Molecular Conformation; Permeability; Protein Binding; Tacrine | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Catalytic Domain; Cattle; Cell Death; Cell Line, Tumor; Cell Survival; Cholinergic Agents; Cholinesterase Inhibitors; Esters; Glutamic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Neuroprotective Agents; Permeability; Piperidines; Protein Binding | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Importance of physicochemical properties for the design of new pesticides.
Topics: Anabasine; Animals; Biological Availability; Cell Membrane Permeability; Chemical Phenomena; Drug Design; Humans; Imidazoles; Insecticides; Neonicotinoids; Nitro Compounds; Pesticides; Quantitative Structure-Activity Relationship; Receptors, Nicotinic | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antineoplastic Agents; Butyrylcholinesterase; Calcium; Cell Death; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Okadaic Acid; Peptide Fragments; Phenothiazines; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Hybrids of oxoisoaporphine-tacrine congeners: novel acetylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Aporphines; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Horses; Humans; Models, Biological; Tacrine | 2011 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Cinnamates; Enterocytes; Humans; Hydrophobic and Hydrophilic Interactions; Intestinal Absorption; Kinetics; Models, Biological; Molecular Conformation; Osmolar Concentration; Phenols | 2012 |
Novel oxoisoaporphine-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Membranes, Artificial; Models, Molecular; Molecular Structure; Permeability; Protein Binding | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Synthesis and evaluation of 4-hydroxyl aurone derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Blood-Brain Barrier; Chelating Agents; Copper; Humans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Swine | 2016 |
Multitarget-directed oxoisoaporphine derivatives: Anti-acetylcholinesterase, anti-β-amyloid aggregation and enhanced autophagy activity against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Aporphines; Autophagy; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Protein Aggregates; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Isoflavones; Mannich Bases; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Aurone Mannich base derivatives as promising multifunctional agents with acetylcholinesterase inhibition, anti-β-amyloid aggragation and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Mannich Bases; Neuroprotective Agents; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
DL-3-n-butylphthalide-Edaravone hybrids as novel dual inhibitors of amyloid-β aggregation and monoamine oxidases with high antioxidant potency for Alzheimer's therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Antipyrine; Benzofurans; Binding Sites; Blood-Brain Barrier; Edaravone; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Structure, Tertiary | 2017 |
Multifunctional thioxanthone derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cell Line; Cholinesterase Inhibitors; Humans; Kinetics; Models, Molecular; Monoamine Oxidase Inhibitors; Thioxanthenes; Xanthones | 2017 |
Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia.
Topics: Alzheimer Disease; Animals; Brain Ischemia; Calcium Channel Blockers; Cholinesterase Inhibitors; Donepezil; Glutamates; Hippocampus; Humans; Indans; Neuroprotective Agents; Piperidines; Rats; Solid-Phase Synthesis Techniques | 2017 |
Design, synthesis and evaluation of novel ferulic acid-O-alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Coumaric Acids; Drug Design; Eels; Humans; Memory Disorders; Mice; PC12 Cells; Rats | 2017 |
Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Electrophorus; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quinolines; Swine | 2017 |
Design, synthesis and biological evaluation of phthalimide-alkylamine derivatives as balanced multifunctional cholinesterase and monoamine oxidase-B inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amines; Binding Sites; Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Phthalimides; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of 2-acetyl-5-O-(amino-alkyl)phenol derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Benzophenones; Binding Sites; Blood-Brain Barrier; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Hydrogen Peroxide; Inhibitory Concentration 50; Molecular Docking Simulation; Monoamine Oxidase; Neuroprotective Agents; PC12 Cells; Permeability; Phenols; Piperazines; Protein Structure, Tertiary; Rats; Structure-Activity Relationship | 2017 |
Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Kinetics; Male; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Peptide Fragments; Protein Aggregates; Range of Motion, Articular; Structure-Activity Relationship; Thiocarbamates | 2018 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Survival; Chalcones; Chelating Agents; Copper; Drug Design; Flurbiprofen; Humans; Lipopolysaccharides; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Nitric Oxide; Peptide Fragments; Recombinant Proteins; Structure-Activity Relationship | 2018 |
MF-8, a novel promising arylpiperazine-hydantoin based 5-HT
Topics: Dose-Response Relationship, Drug; Humans; Hydantoins; Molecular Structure; Piperazines; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship | 2018 |
Multifunctional 5,6-dimethoxybenzo[d]isothiazol-3(2H)-one-N-alkylbenzylamine derivatives with acetylcholinesterase, monoamine oxidases and β-amyloid aggregation inhibitory activities as potential agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Blood-Brain Barrier; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Permeability; Protein Aggregates; Recombinant Proteins; Structure-Activity Relationship; Thiazoles | 2018 |
Discovery of novel anti-tuberculosis agents with pyrrolo[1,2-a]quinoxaline-based scaffold.
Topics: Antineoplastic Agents; Antitubercular Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrroles; Quinoxalines; Structure-Activity Relationship | 2018 |
Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors.
Topics: Alzheimer Disease; Blood-Brain Barrier; Cholinesterase Inhibitors; Cholinesterases; Chromones; Drug Design; Hep G2 Cells; Humans; Ligands; Molecular Docking Simulation; Molecular Targeted Therapy; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cholinesterase Inhibitors; Drug Design; Drug Discovery; Electrophorus; Flurbiprofen; Humans; Mannich Bases; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Rats; Swine | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
The development of 2-acetylphenol-donepezil hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Design; Drug Development; Humans; Kinetics; Models, Molecular; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2019 |
Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Biological Transport; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Chelating Agents; Cholinesterase Inhibitors; Coordination Complexes; Copper; Drug Design; Female; Humans; Male; Memory Disorders; Mice; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Protein Binding; Scopolamine; Structure-Activity Relationship | 2019 |
Effect of dihydroxyphenylalanine, imipramine and coffeine on the light induced decrease in nocturnal serotonin N-acetyltransferase in the rat pineal gland.
Topics: Acetyltransferases; Animals; Caffeine; Darkness; Dihydroxyphenylalanine; Imipramine; Light; Male; Pineal Gland; Rats; Serotonin | 1976 |
[Effect of echinopsin and adepren on motor activity in rats].
Topics: Aminoquinolines; Amphetamine; Animals; Antidepressive Agents; Caffeine; Dose-Response Relationship, Drug; Imipramine; Male; Motor Activity; Nialamide; Quinolines; Rats | 1978 |
Organic dissociative syndrome associated with antimigraine pharmacotherapy.
Topics: Adolescent; Analgesics; Aspirin; Barbiturates; Caffeine; Dissociative Disorders; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipramine; Migraine Disorders; Phenacetin; Substance-Related Disorders | 1991 |
[Effect of substances modifying calcium movement on the contractility of cultured cardiac cells].
Topics: Animals; Caffeine; Calcium Channel Blockers; Cells, Cultured; Diltiazem; Histamine; Imipramine; Ion Channels; Isoproterenol; Myocardial Contraction; Nifedipine; Phenylephrine; Rats; Verapamil | 1985 |
Electrophysiological and neurochemical investigations on the action of carbamazepine on the rat hippocampus.
Topics: Anesthetics, Local; Animals; Caffeine; Carbamazepine; Depression, Chemical; Glutamates; Glutamic Acid; Hippocampus; Imipramine; In Vitro Techniques; Male; Rats; Rats, Inbred Strains; Receptors, Cell Surface; Receptors, Purinergic; Sodium; Synaptic Transmission; Tritium | 1985 |
Effects of psychoactive drugs on operant responding and non-operant activity of rats with hippocampal system damage.
Topics: Animals; Behavior, Animal; Caffeine; Conditioning, Operant; Dextroamphetamine; Hippocampus; Imipramine; Male; Methylphenidate; Pentobarbital; Psychotropic Drugs; Rats; Rats, Inbred Strains; Sodium Chloride | 1986 |
Pharmacologically induced alterations of cortical and subcortical evoked potentials compared with physiological changes during the awake-sleep cycle in cats.
Topics: Amphetamine; Anesthetics; Animals; Atropine; Auditory Cortex; Caffeine; Cats; Central Nervous System Stimulants; Cerebral Cortex; Chloralose; Chlorpromazine; Computers; Dihydroxyphenylalanine; Electroencephalography; Evoked Potentials; Hippocampus; Imipramine; Lysergic Acid Diethylamide; Pentobarbital; Perphenazine; Physostigmine; Sleep; Thalamus; Tranquilizing Agents; Visual Cortex; Wakefulness | 1967 |
Prevention by antidepressant drugs of reserpine effect on pyridine nucleotide metabolism.
Topics: Aminopyrine; Amitriptyline; Amphetamine; Animals; Antidepressive Agents; Atropine; Benactyzine; Caffeine; Chlorpheniramine; Chlorpromazine; Female; Hexobarbital; Hydralazine; Hypothalamus; Imipramine; Iproniazid; Isoniazid; Liver; Meprobamate; Methacholine Compounds; Morphine; NAD; Niacinamide; Pargyline; Pentobarbital; Phenylbutazone; Phenytoin; Quinacrine; Rats; Reserpine; Tranylcypromine; Tripelennamine; Zoxazolamine | 1966 |
Aggregation of human blood platelets by vasopressin.
Topics: Acetates; Adenosine; Animals; Anticoagulants; Blood Platelets; Caffeine; Carbon Isotopes; Cations, Divalent; Cell Aggregation; Chelating Agents; Citrates; Creatine Kinase; Cyclic AMP; Dogs; Ethylmaleimide; Fibrinogen; Glycols; Hirudins; Humans; Imipramine; Phosphocreatine; Prostaglandins; Rabbits; Serotonin; Swine; Vasopressins | 1972 |
Studies on phosphodiesterase from oxyntic cells of bullfrog gastric mucosa. I. Intracellular localization, partial purification, and properties.
Topics: Ammonium Sulfate; Animals; Anura; Caffeine; Chemical Phenomena; Chemistry; Choline; Cyclic AMP; Gastric Mucosa; Histamine; Hydrogen-Ion Concentration; Imipramine; In Vitro Techniques; Kinetics; Magnesium; Pentagastrin; Phosphoric Diester Hydrolases; Rana catesbeiana; Sulfhydryl Compounds; Theophylline; Time Factors; Tritium | 1973 |
Effect of drugs on the activity of thrombocytes 3,5-cyclic AMP phosphodiesterase.
Topics: 1-Propanol; Adenosine Diphosphate; Adenosine Monophosphate; Aminophylline; Blood Platelets; Caffeine; Chlorpromazine; Cyclic AMP; Desipramine; Dibenzothiepins; Epinephrine; Imipramine; Nortriptyline; Phosphoric Diester Hydrolases; Piperazines; Platelet Adhesiveness | 1974 |
Potentiation of the anticonvulsant action of acetazolamide.
Topics: Acetazolamide; Amphetamine; Animals; Anticonvulsants; Caffeine; Cocaine; Desipramine; Drug Synergism; Electric Stimulation; Electroshock; Ephedrine; Histamine H1 Antagonists; Imipramine; Isoproterenol; Male; Metaraminol; Mice; Morphine; Phenethylamines; Quaternary Ammonium Compounds; Seizures; Stress, Physiological; Tranylcypromine; Tyramine | 1966 |
Flurothyl in mice: seizure, post-convulsive behavior, and interactions with psychotropic drugs.
Topics: Amphetamine; Animals; Atropine; Behavior, Animal; Biperiden; Caffeine; Catalepsy; Central Nervous System Stimulants; Chlordiazepoxide; Chlorpromazine; Diazepam; Electroshock; Haloperidol; Humans; Imipramine; Iproniazid; Meprobamate; Monoamine Oxidase Inhibitors; Motor Activity; Parasympatholytics; Pargyline; Prenylamine; Procyclidine; Rats; Reflex; Reserpine; Seizures; Tranylcypromine | 1968 |
[Psychopharmacologic agents and the sense of smell].
Topics: Amphetamine; Antidepressive Agents; Bromine; Caffeine; Central Nervous System Stimulants; Chlordiazepoxide; Humans; Imipramine; Meclofenoxate; Meprobamate; Methylphenidate; Phenothiazines; Smell; Thioridazine; Tranquilizing Agents | 1968 |
[Anti-fatigue effect of amphetamine and central-stimulating drugs on the performance of mice during prolonged conditioning sessions].
Topics: Amitriptyline; Amphetamine; Animals; Behavior, Animal; Caffeine; Catecholamines; Central Nervous System Stimulants; Conditioning, Psychological; Imipramine; Male; Mice; Nicotine; Pentylenetetrazole; Scopolamine; Strychnine; Sympathomimetics | 1967 |
[Therapy of hypersomnia].
Topics: Amphetamine; Animals; Antidepressive Agents; Appetite Depressants; Bemegride; Caffeine; Cats; Central Nervous System Stimulants; Chlorphentermine; Desipramine; Electroencephalography; Ephedrine; Glycolates; Humans; Hydroxybutyrates; Imipramine; Mice; Narcolepsy; Pemoline; Phentermine; Piperidines; Rabbits; Rats; Sleep Wake Disorders; Strychnine; Sympathomimetics | 1967 |
[Introduction of mass psychology in animals to pharmacology. 6. Mutural relation in simultaneity convulsion and non-convulsin in E1-mice].
Topics: Amphetamine; Animals; Antidepressive Agents; Behavior, Animal; Caffeine; Camphor; Central Nervous System Stimulants; Chlordiazepoxide; Chlorpromazine; Diphenhydramine; Imipramine; Mice; Nikethamide; Pentylenetetrazole; Rodent Diseases; Seizures; Tranquilizing Agents | 1970 |
Brain uptake of metabolites and drugs following carotid arterial injections.
Topics: Acetates; Amino Acids; Animals; Antipyrine; Ascorbic Acid; Aspirin; Barbiturates; Blood-Brain Barrier; Brain; Caffeine; Chloroquine; Cyanides; Ethanol; Imipramine; Lactates; Mescaline; Morphine; Neurotransmitter Agents; Nicotine; Penicillin G; Pharmaceutical Preparations; Phenytoin; Procaine; Pyruvates; Rats | 1971 |
A survey of selected drugs on behavioral performance in ethanol-treated rats.
Topics: Amphetamine; Animals; Caffeine; Conditioning, Operant; Cyproheptadine; Drug Antagonism; Ethanol; Histamine H1 Antagonists; Imipramine; Male; Methylphenidate; Methyltyrosines; Pentylenetetrazole; Piperidines; Pyridines; Rats | 1971 |
Effects of chlorpromazine, imipramine, and quinidine on the mechanical activity of single skeletal muscle fibres of the frog.
Topics: Animals; Anura; Caffeine; Chlorpromazine; Drug Synergism; Electric Stimulation; Imipramine; Methods; Muscle Contraction; Myofibrils; Potassium; Quinidine; Rana temporaria; Tendons | 1972 |
Differential changes in potency of platelet-aggregation inhibitors after preincubation in platelet-rich plasma.
Topics: Adenosine Diphosphate; Amitriptyline; Animals; Caffeine; Chlorpromazine; Diphenhydramine; Dipyridamole; Imipramine; Papaverine; Plasma; Platelet Adhesiveness; Swine; Time Factors; Trifluoperazine | 1974 |
Confirmed identification of biotransformed drugs of abuse in urine.
Topics: Amphetamine; Analgesics; Barbiturates; Biotransformation; Caffeine; Cannabis; Chromatography, Gas; Chromatography, Thin Layer; Codeine; Humans; Hydrogen-Ion Concentration; Imipramine; Indicators and Reagents; Methadone; Morphine; Nicotine; Pharmaceutical Preparations; Procaine; Skin; Spectrum Analysis; Substance-Related Disorders; Tranquilizing Agents | 1972 |
The effect of immunosympathectomy on the responses of the mouse to reserpine and various antidepressant and stimulant drugs.
Topics: Amitriptyline; Amphetamine; Animals; Antidepressive Agents; Body Temperature; Caffeine; Hydrazines; Imipramine; Immune Sera; Mice; Mice, Inbred Strains; Monoamine Oxidase Inhibitors; Reserpine; Sympathetic Nervous System | 1972 |
[Pharmacology of the active substances in betel. 3. Experiments with arecaidine].
Topics: Animals; Areca; Behavior, Animal; Bile; Blood Glucose; Blood Pressure; Caffeine; Chlorpromazine; Depression, Chemical; Diuresis; Dogs; Drug Synergism; Efficiency; Glutamates; Hexobarbital; Imipramine; Learning; Mice; Nicotinic Acids; Parasympathomimetics; Perception; Phenothiazines; Plant Extracts; Plants, Medicinal; Psychopharmacology; Rats; Reserpine; Stimulation, Chemical | 1970 |
[Intraspecific aggressive behavior induced by apomorphine in the rat].
Topics: Acepromazine; Age Factors; Aggression; Amitriptyline; Animals; Apomorphine; Atropine; Behavior, Animal; Caffeine; Chlordiazepoxide; Chlorpromazine; Dextroamphetamine; Diazepam; Drug Antagonism; Electroshock; Environment; Haloperidol; Humans; Hydroxyzine; Imipramine; Male; Meprobamate; Morphine; Rats; Reserpine; Sex Factors; Sound; Species Specificity; Thiazines; Thioridazine | 1970 |
[Behavioral dissociation at the level of the relation of ingestion and the number of merycism cycles in sheep].
Topics: Abomasum; Amphetamine; Animals; Antineoplastic Agents; Caffeine; Chlorpromazine; Circadian Rhythm; Depression, Chemical; Digitalis Glycosides; Ephedrine; Feeding Behavior; Imipramine; Iproniazid; Lanatosides; Mescaline; Pentobarbital; Reserpine; Sheep; Stimulation, Chemical; Stomach, Ruminant | 1967 |
[Measurement of the liver blood flow by the implanted double-thermocouple method].
Topics: Adenosine Triphosphate; Animals; Autonomic Agents; Blood Flow Velocity; Caffeine; Carbon Tetrachloride; Cats; Electricity; Glucose; Hot Temperature; Imipramine; Injections, Intravenous; Liver Circulation; Male; Methods; Norepinephrine; Posture; Thiopental; Tranquilizing Agents; Urethane | 1967 |
[Differences on blood pressure responses to drugs in hypertensive and normotensive rats. (1)].
Topics: Animals; Atropine; Azoles; Blood Pressure; Body Weight; Caffeine; Carbamates; Chlorothiazide; Diuretics; Female; Hypertension; Imipramine; Male; Nikethamide; Plethysmography; Rats; Sympatholytics; Sympathomimetics; Vasoconstrictor Agents; Vasodilator Agents | 1967 |
[Pharmacological effects on running performance of rats in different performance reward and different performance conditions].
Topics: Amphetamine; Animals; Barbiturates; Behavior, Animal; Caffeine; Chlordiazepoxide; Chlorpromazine; Imipramine; Meprobamate; Physical Exertion; Rats; Reward | 1965 |
Inhibition of evoked potentials by caudate stimulation and its antagonism by centrally acting drugs.
Topics: Amphetamine; Amygdala; Animals; Bemegride; Caffeine; Cats; Caudate Nucleus; Cerebral Cortex; Chlorpromazine; Electric Stimulation; Electrophysiology; Evoked Potentials; Forelimb; Hippocampus; Hypothalamus; Imipramine; Medulla Oblongata; Mephenesin; Morphine; Neurons; Pentobarbital; Pentylenetetrazole; Picrotoxin; Reticular Formation; Strychnine; Thalamus | 1967 |
Action of antidepressants, stimulants and depressants in the transition from a fixed ratio to a fixed interval schedule of reinforcement.
Topics: Amitriptyline; Amphetamine; Animals; Caffeine; Chlorpromazine; Conditioning, Operant; Diazepam; Doxepin; Imipramine; Male; Psychotropic Drugs; Rats; Rats, Inbred Strains; Reinforcement Schedule | 1983 |
Action of caffeine, d-amphetamine, diazepam and imipramine in a dynamic behavioural situation.
Topics: Animals; Behavior, Animal; Caffeine; Conditioning, Operant; Dextroamphetamine; Diazepam; Imipramine; Male; Rats; Rats, Inbred Strains; Reinforcement Schedule; Reversal Learning | 1983 |
A quantitative method for determining the effects of drugs on spermatozoal motility.
Topics: Caffeine; Humans; Imipramine; Male; Nephelometry and Turbidimetry; Sperm Count; Sperm Motility | 1980 |
Effects of psychotropic drugs on impairment of acquisition of shuttle avoidance produced by pretreatment with pairs of tone signal and shock in mice.
Topics: Animals; Avoidance Learning; Caffeine; Chlorpromazine; Diazepam; Electroshock; Imipramine; Male; Mice; Morphine; Nicotine; Psychotropic Drugs; Signal Detection, Psychological | 1994 |
pH-dependent inhibitory effects of Ca2+, Mg2+, and K+ on Ca2+ efflux mediated by sarcoplasmic reticulum ATPase.
Topics: Adenosine Triphosphatases; Animals; Caffeine; Calcium; Calcium-Transporting ATPases; Dibucaine; Egtazic Acid; Hydrogen-Ion Concentration; Imipramine; Kinetics; Magnesium; Magnesium Chloride; Muscles; Potassium; Potassium Chloride; Rabbits; Ryanodine; Sarcoplasmic Reticulum; Terpenes; Thapsigargin; Time Factors; Trifluoperazine | 1994 |
Mechanisms of Ca2+ antagonism in imipramine-induced toxicity of isolated adult rat cardiomyocytes.
Topics: Animals; Antidepressive Agents, Tricyclic; Caffeine; Calcium; Cells, Cultured; Heart; Hydrogen-Ion Concentration; Imipramine; Male; Myocardium; Potassium; Rats; Rats, Sprague-Dawley | 1998 |
DRUG-INDUCED DISSOCIATION BETWEEN EVOKED RETICULAR POTENTIALS AND THE EEG.
Topics: Amphetamine; Amphetamines; Animals; Antidepressive Agents; Atropine; Brain; Caffeine; Catechols; Central Nervous System Stimulants; Chlordiazepoxide; Chlorpromazine; Electroencephalography; Electrophysiology; Hallucinogens; Humans; Imipramine; Methamphetamine; Methylphenidate; Paraldehyde; Pentobarbital; Pentylenetetrazole; Phenoxybenzamine; Rabbits; Research; Reticular Formation; Scopolamine; Thioridazine; Tranquilizing Agents | 1965 |
PHARMACOLOGICAL PROPERTIES OF THE DESMETHYL DERIVATIVES OF SOME ANTIDEPRESSANTS OF IMIPRAMINE TYPE.
Topics: Amitriptyline; Animals; Antidepressive Agents; Caffeine; Desipramine; Hypothermia; Hypothermia, Induced; Imipramine; Injections, Intraperitoneal; Mice; Nortriptyline; Pentylenetetrazole; Peptic Ulcer; Rats; Research; Reserpine; Selective Serotonin Reuptake Inhibitors; Serotonin; Strychnine; Toxicology; Tranquilizing Agents | 1965 |
Use of the elevated T-maze to study anxiety in mice.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Appetite Depressants; Avoidance Learning; Caffeine; Carbolines; Central Nervous System Stimulants; Conditioning, Classical; Dose-Response Relationship, Drug; Escape Reaction; Imipramine; Inhibition, Psychological; Male; Maze Learning; Mice; Motor Activity; Random Allocation; Reaction Time; Serotonin Agents; Yohimbine | 2004 |
Ethopharmacological evaluation of the rat exposure test: a prey-predator interaction test.
Topics: Adrenergic alpha-2 Receptor Antagonists; Alprazolam; Animals; Anti-Anxiety Agents; Antidepressive Agents; Caffeine; Central Nervous System Stimulants; Diazepam; Escape Reaction; Factor Analysis, Statistical; Fluoxetine; Food Chain; Imipramine; Male; Mice; Motor Activity; Posture; Predatory Behavior; Rats; Rats, Long-Evans; Time Factors; Yohimbine | 2013 |
A proposal for refining the forced swim test in Swiss mice.
Topics: Animals; Antidepressive Agents; Apomorphine; Caffeine; Central Nervous System Stimulants; Desipramine; Disease Models, Animal; Fluoxetine; Imipramine; Immobility Response, Tonic; Male; Mice; Principal Component Analysis; Swimming; Time Factors | 2013 |